DE60224052T2 - Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes - Google Patents

Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes Download PDF

Info

Publication number
DE60224052T2
DE60224052T2 DE60224052T DE60224052T DE60224052T2 DE 60224052 T2 DE60224052 T2 DE 60224052T2 DE 60224052 T DE60224052 T DE 60224052T DE 60224052 T DE60224052 T DE 60224052T DE 60224052 T2 DE60224052 T2 DE 60224052T2
Authority
DE
Germany
Prior art keywords
use according
polymer
solid
water
uric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224052T
Other languages
German (de)
English (en)
Other versions
DE60224052D1 (de
Inventor
Stephen Randall Arlington Holmes-Farley
Steven K. Sudbury BURKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DE60224052D1 publication Critical patent/DE60224052D1/de
Application granted granted Critical
Publication of DE60224052T2 publication Critical patent/DE60224052T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DE60224052T 2001-04-18 2002-04-10 Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes Expired - Lifetime DE60224052T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US284445P 2001-04-18
US30556701P 2001-07-13 2001-07-13
US305567P 2001-07-13
PCT/US2002/011492 WO2002085381A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Publications (2)

Publication Number Publication Date
DE60224052D1 DE60224052D1 (de) 2008-01-24
DE60224052T2 true DE60224052T2 (de) 2008-11-06

Family

ID=26962624

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224052T Expired - Lifetime DE60224052T2 (de) 2001-04-18 2002-04-10 Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes

Country Status (9)

Country Link
US (2) US20030039627A1 (https=)
EP (1) EP1416942B1 (https=)
JP (1) JP2004528332A (https=)
AT (1) ATE380553T1 (https=)
BR (1) BR0209133A (https=)
CA (1) CA2444347A1 (https=)
DE (1) DE60224052T2 (https=)
MX (1) MXPA03009571A (https=)
WO (1) WO2002085381A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
WO2004099288A1 (en) * 2003-05-09 2004-11-18 Carlsberg A/S Polyethyleneimine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
WO2006072054A1 (en) * 2004-12-30 2006-07-06 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
EP1883405A4 (en) * 2005-05-09 2010-01-27 Takeda Pharmaceuticals North A METHODS OF TREATING NEPHROLITHIASIS
US8986669B2 (en) * 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
EP3000460A1 (en) 2005-09-15 2016-03-30 Genzyme Corporation Sachet formulation for amine polymers
EP1945196A2 (en) * 2005-11-08 2008-07-23 Genzyme Corporation Magnesium-containing polymers for hyperphosphatemia
EP2016114A2 (en) * 2006-05-05 2009-01-21 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
AU2007275711A1 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
KR20150024919A (ko) * 2006-11-13 2015-03-09 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
US8163799B2 (en) * 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
JP2010519298A (ja) * 2007-02-23 2010-06-03 ゲンズイメ コーポレーション アミンポリマー組成物
EP2131820A1 (en) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
WO2009078958A1 (en) * 2007-12-14 2009-06-25 Genzyme Corporation Coated pharmaceutical compositions
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
CA2812034C (en) 2010-09-10 2018-10-23 Takeda Pharmaceuticals U.S.A., Inc. Methods for concomitant treatment of theophylline and febuxostat
SI3287133T1 (sl) 2013-06-05 2019-09-30 Tricida Inc. Polimeri, ki vežejo protone,za peroralno dajanje
LT3229816T (lt) 2014-12-10 2020-05-25 Tricida Inc. Protoną prijungiantys polimerai, skirti peroraliniam įvedimui
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
BR112019013364A2 (pt) 2016-12-28 2020-04-14 Fujifilm Corp emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas
CN111225674A (zh) 2017-10-16 2020-06-02 富士胶片株式会社 高磷血症治疗剂
IL319146A (en) 2017-11-03 2025-04-01 Tricida Inc Compositions for and method of treating acid-base disorders
EP4164659B1 (en) * 2021-08-24 2024-03-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4161534B1 (en) * 2021-08-24 2024-11-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271191A (en) * 1979-12-19 1981-06-02 Pierre Fabre S.A. Method of treating hyperuricemia and gout
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
EP0934352B1 (en) * 1996-10-23 2007-05-02 Dow Global Technologies Inc. Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid

Also Published As

Publication number Publication date
US20030039627A1 (en) 2003-02-27
DE60224052D1 (de) 2008-01-24
EP1416942B1 (en) 2007-12-12
JP2004528332A (ja) 2004-09-16
EP1416942A1 (en) 2004-05-12
US20080112918A1 (en) 2008-05-15
CA2444347A1 (en) 2002-10-31
ATE380553T1 (de) 2007-12-15
MXPA03009571A (es) 2004-02-12
BR0209133A (pt) 2004-06-15
WO2002085381A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
DE60224052T2 (de) Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes
DE69833134T2 (de) Verwendung aliphatischer amine zur verminderung von oxalat
DE69818058T2 (de) Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
DE69812681T2 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
DE69434726T2 (de) Polymer zur therapeutischen Anwendung
DE60106623T2 (de) Neue pharmazeutische zusammensetzung
DE602004006892T2 (de) Anionenbindende polymere und ihre verwendungen
DE69828067T2 (de) Kationische polymere zur bindung von toxinen
EP0012804B1 (de) Salze eines zur dauernden Bindung an die Gallensäuren fähigen nicht toxischen aktivierten Anionenaustauscherharzes mit 2-(4'-(p-Chlorbenzoyl)-phenoxy)-2-(methyl)-propionsäure und diese Salze enthaltende Arzneimittel
DE69508449T2 (de) Herstellung von vernetzten Anionaustaucherpartikeln
US20020187120A1 (en) Method for treating gout and reducing serum uric acid
DE69522687T2 (de) Vernetzte polymere enthaltende zusammensetzung zum entfernen von gallensäuren bei patienten
DE69511861T2 (de) Verfahren zur entfernung von gallsaüre von einem patienten sowie die alkylierte zusammensetzungen dafür
US4143130A (en) Method for treating kidney stones
KR100556324B1 (ko) 리파제 억제제 및 담즙산 격리제를 포함하는 약학 조성물
DE112006002617T5 (de) Verfahren zur Herstellung von Core-Shell-Kompositen bzw. Kern-Hüllen-Kompositen mit vernetzten Hüllen und daraus entstehende Core-Shell-Komposite
AU2001289699A1 (en) New pharmaceutical composition
EP0580078A1 (de) Hydrophile Zentren aufweisende Polyvinylamin-Derivate, Verfahren zu ihrer Herstellung sowie die Verwendung der Verbindungen als Arzneimittel, Wirkstoffträger und Nahrungsmittelhilfsstoff
JP2004535384A (ja) 血清グルコースの減少方法
DE112006002618T5 (de) Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
US4395392A (en) Method for treating kidney stones
US4041153A (en) Methods and pharmaceutical preparation for the treatment of hypercholesterolaemia
GB2036553A (en) Pharmaceutical compositions containing polymers of unsaturated carboxylic acids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition